SCHEMBL29676766

SCHEMBL29676766

Cc1cc(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)ncn2)ccc1CNC(=O)c1cn[nH]c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKE Q14164 1/20 0.48
▸ TBK1 Q9UHD2 1/20 0.48
▸ KMT2A Q03164 1/20 0.41
▸ KDM1A O60341 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ BTK Q06187 4/20 0.41
▸ CDK2 P24941 4/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ HSF1 Q00613 1/20 0.40
▸ WNT3A P56704 1/20 0.40
▸ DYRK1B Q9Y463 3/20 0.39
▸ IGF1R P08069 2/20 0.39
▸ WNT1 P04628 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ MAPK14 Q16539 1/20 0.38
▸ FLT3 P36888 3/20 0.38
▸ PRKD1 Q15139 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29676713 0.87 IKBKE (0.47) IKBKETBK1KMT2AKDM1AHDAC1
SCHEMBL16794039 0.86 BTK (0.45) IKBKETBK1KMT2AKDM1AHDAC1
SCHEMBL16794044 0.85 IKBKE (0.49) IKBKETBK1BTKCDK2CCNT1
SCHEMBL16794198 0.82 BTK (0.65) IKBKETBK1BTKCDK2CCNT1
SCHEMBL16794467 0.82 IKBKE (0.44) IKBKETBK1KMT2AKDM1AHDAC1
SCHEMBL16794380 0.81 IKBKE (0.51) IKBKETBK1BTKCDK2CCNT1
SCHEMBL19557886 0.80 IKBKE (0.60) IKBKETBK1BTKCDK2CCNT1
SCHEMBL20445711 0.79 IKBKE (0.48) IKBKETBK1BTKCDK2CCNT1
SCHEMBL20054055 0.78 IKBKE (0.43) IKBKETBK1KMT2ABTKCDK2
SCHEMBL20054019 0.78 IKBKE (0.43) IKBKETBK1BTKCDK2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109096274-B Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases 比奥根MA公司 2022-07-01 — — CN disclosed
Send feedback